Five other drugs to treat gMG have won FDA approval in recent years: eculizumab (Soliris), efgartigimod (Vyvgart), rozanolixizumab (Rystiggo), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq).

In 2007, the US Food and Drug Administration (FDA) approved eculizumab (Soliris ®), a recombinant humanized monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Beyond ...

The monoclonal antibody and anti-C5 complement inhibitor eculizumab is a well-established standard of care to treat PNH and aHUS, rare diseases with an estimated U.S. prevalence of approximately ...

“Individuals living with rare diseases, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis, often have limited access to life-enh ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...